@entity6309 kinetics after single and multiple dosing in XXXX with @entity712 .

@entity1 @entity712 @entity4925 @entity14524 @entity3829 @entity6309
The pharmacokinetics of @entity6309 after single and multiple dosing was studied in 20 @entity1 with @entity712 ( @entity712 ) of NYHA functional class II. @entity6309 100 mg was given 3 times a day for 7 days in 6 @entity1 and for 30 days in the other 14 @entity1 . Plasma pharmacokinetics of total (mainly conjugated) and free @entity14524 was studied after the first dose and on the 3rd, 7th and 30th days of treatment. The urinary recoveries of total @entity14524 , @entity3829 and @entity4925 were measured in 5 @entity1 for 24 h after @entity6309 ingestion on the 1st and 30th days. Plasma pharmacokinetics of @entity6309 did not vary during the repeated administration of the drug. In the course of the treatment, total @entity14524 elimination t1/2 showed no significant variations. The build-up of Cmax, Cmin and AUC of total @entity14524 observed after multiple dosing was as expected on the basis of the interval adopted between the doses of @entity6309 and of the elimination t1/2 of total @entity14524 . Pharmacokinetic parameters of free @entity14524 did not show significant variations during the course of the treatment. The amounts of @entity3829 and @entity4925 recovered in urine on the 1st and 30th days of treatment were similar while the amount of total @entity14524 was greater on the 30th day, the increment mainly reflecting a partial carry over of the less rapidly excreted conjugated @entity14524 from the last previous doses. The results obtained for free @entity14524 plasma levels and for the urinary recoveries of @entity6309 metabolites thus indicated that no saturation of the enzymes involved in @entity6309 metabolism occurred.
